Fractional Exhaled Nitric Oxide Nonsuppression Identifies Corticosteroid-Resistant Type 2 Signaling in Severe Asthma

Am J Respir Crit Care Med. 2021 Sep 15;204(6):731-734. doi: 10.1164/rccm.202104-1040LE.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Administration, Inhalation
  • Adrenal Cortex Hormones / therapeutic use*
  • Adult
  • Aged
  • Anti-Asthmatic Agents / therapeutic use*
  • Asthma / diagnosis*
  • Asthma / drug therapy*
  • Asthma / metabolism
  • Biomarkers / analysis
  • Biomarkers / metabolism
  • Breath Tests
  • Case-Control Studies
  • Cross-Sectional Studies
  • Drug Resistance*
  • Eosinophils / metabolism
  • Exhalation
  • Female
  • Humans
  • Male
  • Middle Aged
  • Nitric Oxide / analysis
  • Nitric Oxide / metabolism*
  • Severity of Illness Index

Substances

  • Adrenal Cortex Hormones
  • Anti-Asthmatic Agents
  • Biomarkers
  • Nitric Oxide

Associated data

  • ClinicalTrials.gov/NCT02883530